SCHEMBL3615224

SCHEMBL3615224

CCc1nn(C2CCOCC2)c2nc(-c3ccnn3-c3cccc(OCCOC)c3)ccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 0.37
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
MKNK1 Q9BUB5 2/20 0.34
PIK3CD O00329 4/20 0.34
PIK3CA P42336 2/20 0.34
PIK3CG P48736 2/20 0.34
PIK3R2 O00459 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3R5 Q8WYR1 1/20 0.34
PIK3R3 Q92569 1/20 0.34
PDE1A P54750 3/20 0.34
PDE1B Q01064 3/20 0.34
PDE1C Q14123 3/20 0.34
TYK2 P29597 2/20 0.33
PDE9A O76083 1/20 0.33
PDE4D Q08499 4/20 0.33
PDE4A P27815 3/20 0.33
PDE4B Q07343 3/20 0.33
PDE4C Q08493 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609110 0.92 CSNK1A1 (0.37) CSNK1A1CSNK1DCSNK1EMKNK1PIK3CD
SCHEMBL3608097 0.91 PDE1B (0.37) PDE1APDE1BPDE1CTYK2PDE9A
SCHEMBL3597577 0.91 MKNK1 (0.40) CSNK1A1CSNK1DCSNK1EMKNK1PDE1A
SCHEMBL3615916 0.88 BCHE (0.41) CSNK1A1CSNK1DCSNK1EMKNK1PIK3CD
SCHEMBL14362846 0.86 PDE9A (0.32) CSNK1A1CSNK1DCSNK1EPIK3CDPIK3CA
SCHEMBL3599851 0.85 PIK3CA (0.35) CSNK1A1CSNK1DCSNK1EPIK3CDPIK3CA
SCHEMBL3616556 0.85 PDE1C (0.42) PDE1APDE1BPDE1CTYK2PDE9A
SCHEMBL3612172 0.85 PIK3CD (0.40) CSNK1A1CSNK1DCSNK1EPIK3CDPIK3CA
SCHEMBL3609189 0.85 PDE1C (0.39) PDE1APDE1BPDE1CPDE9APDE4B
SCHEMBL3607885 0.83 PDE1C (0.45) PIK3CDPDE1APDE1BPDE1CPDE9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US claimed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US claimed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US claimed
US-20070254913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-01 US claimed
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US claimed
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7723348-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2010-05-25 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-7432266-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2008-10-07 US disclosed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US disclosed
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS HOPPER ALLEN 2008-08-28 US disclosed
WO-2007123953-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-11-01 WO disclosed
WO-2007123953-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-11-01 WO disclosed
US-20070254913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-01 US disclosed
US-20070254913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-01 US disclosed
US-20070254913-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254913-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 CSNK1A1 3364/4885CSNK1D 2901/4885CSNK1E 2795/4885
US-20080207660-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE12 CSNK1A1 3364/4885CSNK1D 2901/4885CSNK1E 2795/4885
US-20060154960-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 CSNK1A1 3364/4885CSNK1D 2901/4885CSNK1E 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.